- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Evaluating Access to Care and Service Coverage Associated With Reproductive Medicine
Dr. Chervenak evaluates access to care in the current health care system for patients seeking treatment in reproductive medicine.
EP: 1.Clinician Challenges In Infertility Diagnosis
EP: 2.Emerging Trends and Technology Within Reproductive Medicine Landscape
EP: 3.Evaluating Access to Care and Service Coverage Associated With Reproductive Medicine
EP: 4.Availability of Coverage Impacting Patients Seeking Infertility Treatment
EP: 5.Strategies for Navigating Socioeconomic Factors In Reproductive Medicine
EP: 6.Optimizing Health Benefit Design and Patient Outcomes In Infertility Management
Joseph Chervenak, MD, MBA, discusses his work presented at a specialty conference, focusing on the role of large language AI models in addressing the problem. He notes historical challenges, with fertility care traditionally serving a small affluent population. The gap between patient needs and available services is underscored, presenting both a challenge and an opportunity for the future. The discussion extends to the variability in health benefit designs across states and individuals, especially concerning insurance coverage for in vitro fertilization (IVF). Mandates, though important, have exceptions, requiring careful consideration of each patient's financial situation. Dr. Chervenak concludes by highlighting IVF as an effective but expensive treatment, with success rates influenced by factors such as the age of the female partner and reproductive history. The complex landscape of healthcare coverage and the need for personalized financial reviews are central themes in addressing these reproductive health challenges.
Video synopsis is AI-generated and reviewed by Managed Health Care Executive editorial staff.
Can Lecanemab Succeed Where Aduhelm Failed?
September 28th 2022The announcement of positive phase 3 results for the investigational Alzheimer’s disease drug comes against a backdrop of Aduhelm flaming out. Both drugs are predicated on the theory that Alzheimer’s is caused by beta-amyloid deposits.
Read More
Value-Based Decision-Making in Metastatic Breast Cancer
September 16th 2021In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.
Read More
